Ron Squarer
Chief Executive Officer | Boulder, Colorado, United States
Professional Overview
Ron Squarer is an experienced biotechnology executive currently serving as the Chief Executive Officer of Array BioPharma Inc. He also holds several board-level positions, including as Board Chair of ADC Therapeutics SA and Deciphera Pharmaceuticals, as well as a member of the Board of Directors at Travere Therapeutics. Squarer's expertise spans commercial operations, strategic leadership, and driving innovation in the pharmaceutical industry.
Experience Summary
Current Role
As Chief Executive Officer of Array BioPharma Inc., Squarer is responsible for the overall strategic direction and operational execution of the company. Under his leadership, Array BioPharma has become a leading biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other life-threatening diseases.
Career Progression
Prior to joining Array BioPharma, Squarer held the role of Chief Commercial Officer at Hospira, a global medical device and pharmaceutical company. In this capacity, he was instrumental in driving the company's commercial strategy and expanding its global presence. Squarer's diverse background also includes various leadership positions within the biotechnology industry, where he has demonstrated a proven track record of successful portfolio management and commercialization of innovative therapies.
Academic Background
Squarer holds a Bachelor of Science degree from the University of Colorado Boulder, where he specialized in Molecular, Cellular, and Developmental Biology.
Areas of Expertise
- Pharmaceutical and biotechnology industry expertise
- Strategic leadership and commercial operations
- Driving innovation in targeted small molecule drug development
- Portfolio management and commercialization of novel therapies
- Board-level governance and oversight
Professional Impact
Throughout his career, Squarer has made significant contributions to the biotechnology industry. Under his leadership, Array BioPharma has achieved notable milestones, including the successful commercialization of several targeted cancer therapies. Additionally, Squarer's board-level roles have allowed him to provide strategic guidance and oversight to other leading biopharmaceutical companies, further cementing his reputation as a respected industry leader.
Conclusion
With his extensive experience, strategic vision, and proven track record of driving innovation and commercial success, Ron Squarer is well-positioned to continue leading Array BioPharma and contributing to the advancement of the biotechnology industry.
